RxDoctor Payments Data

Hirenkumar Shah, MD

Internal Medicine · Frederick, MDNPI 1093742801

Payments from drug & device makers

$2,608in general payments, 2019–2025

Across 133 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$421
  • Lilly USA, LLC$235
  • Amgen$227
  • GSK$194
  • Madrigal Pharmaceuticals$117
  • Radius Health, Inc.$112
  • plus $1K from 34 others

What the payments were for

  • Food & beverage$2,608100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,608 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$652,548
Medicare patients
887
Services billed
10,552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide146$252,766
EliquisApixaban192$200,612
JardianceEmpagliflozin47$64,098
XareltoRivaroxaban36$54,625
TrulicityDulaglutide17$29,005
FarxigaDapagliflozin Propanediol25$26,969
JanuviaSitagliptin Phosphate20$21,194
LinzessLinaclotide13$18,777
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$16,115
EntrestoSacubitril/Valsartan14$14,910
Victoza 3-PakLiraglutide13$14,384
Liraglutide12$12,018
Rosuvastatin Calcium409$10,259
Incruse ElliptaUmeclidinium Bromide15$9,860
Tresiba Flextouch U-200Insulin Degludec14$8,460

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$421$252,766146 claims
PfizerEliquis, Paxlovid$90$203,409208 claims
Boehringer IngelheimJardiance$108$64,09847 claims
Lilly USA, LLCTrulicity$235$29,00517 claims
AstraZenecaFarxiga$86$26,96925 claims
AbbVieLinzess, Synthroid$70$26,651121 claims
GSKTrelegy Ellipta, Incruse Ellipta$194$25,97536 claims
MerckJanuvia$45$21,19420 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$30$4,893451 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →